The $2,000 Medicare Part D cap — what actually changes in 2026

The Inflation Reduction Act of 2022 (IRA) made the largest changes to Medicare Part D since the program began in 2006. The biggest change — the $2,000 annual out-of-pocket cap — took full effect on January 1, 2025. For 2026, the cap rises slightly with inflation indexing; check Medicare.gov for the exact figure. Here’s what actually changes for patients.

The $2,000 cap in plain English

Before 2025, Medicare Part D had no upper limit on annual out-of-pocket drug costs. Patients taking expensive specialty drugs could pay $8,000-$15,000+ per year out of pocket, even with coverage. Now, once you’ve spent $2,000 on covered drugs in a calendar year, you pay $0 for the rest of the year.

The cap counts your deductible, copays, and coinsurance — the money you actually pay. Premiums do not count toward the cap.

What this means by patient type

• Patients on 1-2 affordable generics: You probably won’t hit $2,000, so nothing changes for you.
• Patients on expensive brands or specialty drugs: Life-changing. Your worst-case annual spend is capped. A Humira patient previously paying $3,000-$5,000/year drops to $2,000 total.
• Patients in the former “donut hole”: The donut hole (coverage gap) is gone. The old 4-phase Part D structure (deductible → initial coverage → gap → catastrophic) is now 3 phases with a hard cap at the end.

Other IRA changes patients see

1. Medicare Part D insulin capped at $35/month — all covered insulin, starting 2023. Already in effect.
2. Free vaccines under Part D — starting 2023. Shingrix, RSV, Tdap, and more. Check your plan’s list.
3. Medicare price negotiation on specific drugs — first 10 negotiated prices take effect January 1, 2026: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, Fiasp / NovoLog. Your 2026 copay on these should drop.
4. Smoothing option — you can now choose to pay your annual out-of-pocket evenly across 12 months instead of all upfront. Call your plan to opt in.

What hasn’t changed

• Prior authorization still exists. The IRA didn’t eliminate PA, step therapy, or formulary tiers.
• Premiums may rise. Plans are absorbing more cost post-cap; some have raised premiums. CMS applied a premium stabilization adjustment for 2025-2026.
• Commercial insurance is unaffected. The cap applies only to Medicare Part D (including MA-PD). Employer plans and marketplace plans have their own rules.
• Copay cards still don’t work on Medicare. Federal Anti-Kickback Statute still applies.

Watch for this trap

The $2,000 cap is for covered drugs only. If your plan excludes a drug (non-formulary), money you spend buying it out-of-pocket doesn’t count toward the cap. Before you assume a drug counts, check your plan’s formulary.

Also: if you use GoodRx or pay cash at Cost Plus, those fills don’t count toward the cap. With the cap so low now, staying on Medicare usually beats cash-paying even for pricier generics.